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 Peripheral nerve lesions caused by trauma often require the removal of the injured 
segment of nerve and subsequent repair by surgery. Nerve injuries that produce large 
gaps require a “bridge” to guide axon growth and reinnervation. Harvested autografts are 
currently the gold standard for bridging that gap but they have drawbacks including 
donor site morbidity, limited donor sites, and inconsistent efficacy. Surgically implanting 
a nerve guidance conduit is an alternative solution to grafting nerve conduits and such 
devices are presently available. However, many of them suffer from significant 
drawbacks such as nondegradable properties, nerve compression, complex fabrication 
techniques, and a lack of versatility in exchanging drugs. A bioresorbable multidrug 
delivery conduit that relies on the mechanics of diffusion has been developed to bridge 
the nerve gap and locally deliver neurotrophins and other regeneration promoting drugs 
to the regeneration site. Conduit design, drug delivery modelling, manufacturing 
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Poor recovery from peripheral nerve injuries continues to be a major cause of life-
long loss of function by the resulting nerve damage. A degeneration process known as 
Wallerian degeneration occurs at serious peripheral injury sites prior to the regeneration 
of nerve fibers [1]. The process involves fragmentation of axons and the myelin sheath, 
leaving behind a column of collapsed Schwann cells. These cells play a vital role in the 
following regeneration process by producing necessary neurotrophins such as nerve 
growth factor (NGF) that aid the healing process. Minimizing the period of degeneration 
is essential to successful functional recovery. As the regeneration process begins, axon 
endings use the Schwann cells as guides to complete the reinnervation process.  
However, serious injuries that result from laceration of peripheral nerves often result 
in a nerve gap greater than one centimeter following the nerve degeneration process. In 
such cases, regenerating axons are no longer restricted to their original sheaths and they 
lose their natural guides, allowing them to wander into surrounding tissue. The 
consequence is often failed reinnervation of the necessary organs and tissues resulting 
from incomplete neurological recovery. Regenerating axons may successfully bridge 
these long gaps spontaneously on occasion. However, creating a guide, whether a nerve 
graft or artificial conduit can greatly minimize the amount of scarring that occurs and 
significantly increase the odds for successful recovery. The reinnervation process 
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requires both physical and cell signal guidance to ensure proper growth.  
The success of return of function to organs following reinnervation is time-sensitive. 
Many of the end organs can undergo their own degeneration and muscle fibers atrophy by 
~70% in cross-sectional area by two months after nerve severance. Motor endplates 
typically will be preserved at least a year after denervation. As a result, it is vital that the 
reinnervation process occur as quickly as possible. 
1.1. Neurotrophic Factors and Other Drugs 
Traditionally, axon regeneration rates have been assumed to be fairly constant at 
1mm per day. However, regeneration tests under various factors have reported a spectrum 
of rates varying from as low as 0.5mm per day up to 9mm per day. While some of this 
variation can be attributed to location relative to the proximal and distal stumps and 
varying measurement techniques, a key factor to the success of the regeneration process 
is the presence of essential neurotrophins and growth factors. Neurotrophins such as NGF 
have been identified as cell-signaling molecules that have the ability to guide axons as 
they grow [2]. Additionally, they provide a stimulus for growth of advancing axons and 
studies have shown significant increase in growth rates with the presence of these growth 
factors [3]. One study shows that when sciatic nerve segments are exposed within a 
bioactive range of 5-50ng/mL of NGF, there are significant improvements to the fiber 
density and width [4]. An alternate study indicated that there were synergistic effects in 
combining glial cell line-derived neurotropic factor (GDNF) and NGF [5]. When dorsal 
root ganglion (DRG) cells were treated with these factors within a range of 0.1ng/mL to 
10ng/mL, the resulting cells showed significant length and density growth improvements.  
Alternate drugs have also shown promise in the nerve regeneration process. 
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Tacrolimus (FK506) is a common immunosuppressant drug, but it has also been tested in 
sciatic nerve repair [6]. While tacrolimus showed marginal benefit in the reinnervation 
process, it displayed significant benefits to functional recovery after reinnervation. Some 
studies have even seeded artificial nerve guides with Schwann cells to guide axons and 
improve the regeneration process [7]. Assisted delivery of such drugs or cellular 
transplants will be essential in returning full function to peripheral nerve injury sites. 
There is still much debate about optimal drug and growth factor selections to promote 
nerve regeneration. Consequently, developing a delivery vehicle that can easily alternate 
drugs based on bioactivity results will greatly accelerate peripheral nerve injury research. 
1.2. Nerve Grafting 
In cases where the nerve lesion is too large to suture the nerve endings together 
without tension, autologous nerve grafts have been seen as a standard of care. The 
procedure involves harvesting nerve tissue from other locations on the body and 
reconstructing the injured section. While these grafts dramatically improve the chances of 
successful recovery compared to an untreated injury, they do have significant downsides. 
First, they require a donor site; autologous nerve grafts are often elected over allografts to 
reduce the risk of a negative autoimmune response. The result is an additional injury that 
must heal and regain function and there are limited harvest sites available and no 
guarantees that the donor graft will support axonal regeneration [8]. In addition, larger 
nerve grafts require additional tissue and ideal donor sites of the required volume are 
often lacking. There have been attempts to synthesize a combination of natural and 
synthetic grafting techniques. In one study, chemically extracted acellular allogenic nerve 
grafts that were implanted with autologous mesenchymal stem cells revealed functional 
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recovery after 6 months and results comparable to autologous nerve grafts [9]. These 
hybrid grafts were able to introduce a secondary donor site to the autograft and provide 
sufficient tissue to fill the injury site. However, the introduction of foreign tissue and 
possibility of rejection required the use of immunosuppressive agents, significantly 
increasing the risk of infection and other systemic effects. While grafts have been shown 
to provide a feasible option to bridge a nerve lesion, they do have drawbacks that drive 
the need for more innovative solutions. 
1.3. Guidance Conduits 
An alternative solution to tissue grafts is providing a guidance conduit to promote 
axon innervation. These conduits are surgically implanted into the donor site and act as a 
bridge between the nerve endings. Being able to fabricate conduits to site-specific 
geometries offers significant benefits to autografts which depend on the available donor 
tissue. Nerve guidance conduits are currently commercially available and research on 
these devices has been ongoing since the 1980s. Studies have shown that these conduits 
provided mechanically stable structures that are easily sterilized and performed their 
engineering functions. The earliest clinical attempts of using silicone tubes provided a 
path for the nerve axons to regenerate and connect with their distal stumps [10]. 
However, one problem that plagued nonresorbable devices such as these was a 
compression of the nerve and tension at the suture sites following reinnervation. Another 
study used devices constructed of poly-vinyl alcohol (PVA), a material that is easily 
sterilized and able to successfully reinnervate a nerve lesion. [11]. Again, the problems 
occur as the reinnervated injury grows in tissue mass; the conduit is no longer needed but 
the only solution to remove the now restricting conduit is through surgery. The need to 
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remove the device in a later operation greatly reduces the appeal of nondegradable 
devices. Conduits constructed of bioresorbable materials avoid this issue by degrading 
within the body through natural mechanisms over time. These conduits can be made of 
natural or synthetic material. To demonstrate one example, collagen conduits are 
commercially available and have been shown to repair nerve gaps up to 20mm [12]. 
Nonetheless, because these conduits can take up to 48 months to degrade, similar 
compression problems that persist in nondegradable conduits persist. While a secondary 
surgery is not required to remove the device because it can be fully resorbed after the 
material lifetime, regeneration of the lesion site is not ideal.  
Polyglycolic acid (PGA) conduits provide a dramatically decreased degradation time 
compared to collagen conduits; the material maintains structural integrity for 1-2 months 
and loses total mass in a little over 6 months. Yet, existing devices encountered poor 
functional motor recovery from these devices. The reduced degradation time ended up 
being a key limitation to the recovery process as mechanical properties were lost before 
the proximal and distal stumps could reconnect. Literature has shown that there have 
been many attempts to optimize degradation rates by testing various materials. An ideal 
balance lies in providing mechanical stability while the nerve is regenerating, but then 
allowing for expansion and tissue growth once innervation occurs.  
1.4. Local Delivery of Regeneration-Promoting Drugs 
Introduction of neurotrophic factors during the reinnervation process in conjunction 
with bioresorbable conduits has the potential to provide the physical and signal guidance 
that nerve axons require to regenerate properly. Polylactic-co-glycolic acid (PLGA) has 
been a highly attractive polymer for drug delivery. The majority of current nerve conduit 
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devices using PLGA consist of microsphere or nanosphere drug encapsulation techniques 
that incorporate its degradation process into the release of drugs to the nerve injury site 
[13]. These elegant designs have multiple fabrication methods, including emulsification-
solvent evaporation, spray-drying, solvent-casting, and extrusion. Significant progress 
has been made in determining ideal parameters to produce a conduit that releases a 
specific drug and dosage effectively. However, many of these devices require 
manufacturing techniques that are not practical for large-scale production. Additionally, 
the complex processes involved in fabrication and tuning for specific drug release 
diminish the ability to alternate drugs without completely redesigning each conduit. 
There has been little progress in correlating release rate parameters with specific drug 
chemistry. As a result, these microsphere and nanosphere devices have not proven to be a 
feasible solution in the present nerve regeneration scope. 
The status of drug delivery and axonal growth to promote peripheral nerve 
regeneration is still in a stage of optimization. While certain drugs provide significant 
benefits to growth rates and mass, it is still relatively unknown which of these drug 
combinations and dosages result in ideal regeneration. This statement is especially valid 
for local drug delivery. As a result, nerve conduit development is as much of a search for 
a clinical device as it is for a research device to help identify optimal pharmaceutics for 
local delivery.  
1.5. Material Selection 
In addition to the materials discussed above, other materials that have been used to 
build functional nerve guidance conduits include polycaprolactone (PCL), 
polyhydroxybutyrate (PHB), polyurethane, chitosan, fibrin, silk, and others [14]. 
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Biopolymers provide biocompatible characteristics and can often tailor mechanical 
properties that are complimentary to the regenerating nerve. Alternatively, synthetic 
materials, while not immediately as biocompatible, provide further opportunity to tune 
parameters such as degradation rate, porosity, and microstructure. Additional mechanical 
properties that have been taken into consideration are tensile strength, suturability, 
surface chemistry, and ease to embed bioactive cues into the conduits. 
Polylactic-glycolic acid (PLGA) is a highly favored synthetic polymer because of its 
long clinical experience, tunable degradation characteristics, and ability to sustain long-
term delivery methods. The material undergoes hydrolysis of ester linkages in water and 
breaks down into lactic acid/glycolic acid. Both of these original monomers are by-
products of natural metabolic processes so the body can effectively deal with them. PGA 
can be converted to metabolites by the body and PLA can be cleared through the 
tricarboxylic acid cycle [15]. A vital characteristic of PLGA is its controllable 
degradation rate. Depending on the PLA-PGA ratio, the half-life of the copolymer can 
vary from 6 months down to 2 weeks [16]. The appropriate degradation rate can be 
chosen depending on a target delivery period in addition to the material’s degradation 
during the conduits’ manufacturing and processing time. PLGA has been used 
extensively in the development of nanosphere drug delivery so we know it has favorable 
properties likely to deliver the bioactive cues and growth factors we desire. 
1.6. Prior Work 
The work discussed in this thesis is in continuation to prior work performed in Dr. 
Jay Agarwal’s and Dr. Bruce Gale’s lab by Keng-Min Lin [17]. This section will 
highlight key methods and outcomes from the result of that work. 
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1.6.1. Initial Diffusion Model 
A diffusion model based on Fick’s Diffusion was developed to predict the drug 
release behavior of the nerve conduits. The theory and construct of the model will be 
discussed later in the modelling section.  This model provided an expected diffusion rate 
that device release rates were benchmarked against. Shortcomings to the existing 
diffusion model were primarily due to the fact that this model was constructed in a 
manner that had to be rebuilt every time an input parameter was changed. This model 
also did not explore comparisons between in vitro collection concentrations and in vivo 
exposure concentrations of the drugs being delivered. 
1.6.2. PDMS Conduit Delivery Devices 
This project initially tested devices constructed of polycarbonate-urethane (PCU) 
and poly-di-methyl-siloxane (PDMS). A PCU tube was heat extruded and then cut to 
length to form the guidance conduit and a PDMS drug reservoir was constructed around 
it. The behavior and manufacturing techniques with PDMS are well known and these 
tests explored the difference between diffusion through a permeable membrane vs. 
diffusion through controlled holes. The membranes tested were constructed of 
polyethersulfone (PES). A series of release tests was performed with these devices and 
the results showed that devices with the PES membrane had a higher diffusion rate than 
the diffusion hole. In addition, the diffusion patterns between devices with and without 
membranes was very similar. Both of them had a significant initial burst, regardless of 
the target diffusion rate. As a result, it was concluded that using a diffusion membrane 
did not contribute to sustaining a consistent extended release. 
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1.6.3. PLGA Conduit Delivery Devices 
In continuing the development of PDMS devices, devices were fabricated from 
PLGA as well. A molding process was used to produce the conduit and drug reservoir. 
First, PLGA pellets were dissolved in an acetone-ethanol emulsion and then molded into 
tubes. They were then cut to size and placed concentric to one another. The ends were 
sealed to form a drug reservoir between the two lumens. A detailed process of the 
updated and refined manufacturing techniques will be described later in the 
manufacturing methodology section. The sealing of the device reservoirs required the use 
of nondegradable sealants and was not fully bioresorbable, but it suited the functions 
necessary to test the release kinetics of the device. Release from these devices showed 
similar release patterns to the PDMS devices, with a large initial burst effect. However, 
the deviations between tests were significant and prompted the need to improve the 
reliability of drug release. These devices all consisted of a single drug reservoir to deliver 
an individual drug to the injury site. 
1.7. Conduit Improvement and Innovative Work 
The work in this thesis proposes new manufacturing techniques and functional 
improvements to nerve conduits and continues on the prior work done in Dr. Jay 
Agarwal’s and Dr. Bruce Gale’s labs. There are major benefits in providing a guidance 
conduit that can independently deliver multiple localized drugs to the injury site. 
Additionally, there has not been enough testing performed to understand the unknown 
effects of combining multiple drugs together in the delivery reservoir so a dual reservoir 
system will provide a delivery system for multiple drugs until these effects are studied. A 
bulk diffusion delivery device will provide flexibility in easily alternating drugs as well 
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as precision in using traditional fluid mechanics to control delivery rather than complex 
polymer degradation (Figure 1.1). 
1.8. Thesis Overview 
This thesis explains the derivation and dependencies that were demonstrated in the 
diffusion model. The model was then used to benchmark diffusion kinetic release tests. 
The fabrication methodology will discuss the refinement of PLGA conduit formation, end 
cap formation, and solvent welding of the drug reservoirs. Additional manufacturing 
techniques that were developed to drill diffusion holes and minimize PLGA’s dynamic 
properties when exposed to sterilization, hydrolysis, and in vivo conditions are also 
discussed. A series of four diffusion tests that were conducted to verify drug delivery 
15μm Diffusion Holes 
Drug Reservoirs 
Inner Guidance Conduit 
 
Figure 1.1 Dual drug delivery mouse conduit 
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from the nerve conduits will be summarized and the analysis, results, and conclusion will 
provide a clearer justification as to whether diffusion is a reliable delivery method for 
peripheral nerve regeneration. PLGA’s suitability and challenges that arise from using 
this untraditional engineering polymer in this type of conduit device is also detailed. 
Overall, the efficacy of drug delivery through a PLGA device that uses diffusion holes to 








2. MULTIDRUG DELIVERY CONDUIT 
2.1. Diffusion Modelling 
Using basic diffusion as the primary mode of drug release has been relatively 
unexplored for peripheral nerve injuries. Drug delivery rates from devices are dependent 
on geometric factors as well as the diffusion coefficients of drugs supplied. This approach 
provides a much simpler release model for a device that is designed to discharge drugs. 
The original mathematical model developed to model the release of drugs from these 
devices was built with Microsoft Excel and worked with fixed iteration intervals. The 
primary improvements that were made from the existing model to the current model 
involved restructuring the model to a foundation of dependent variables that allows it to 
be adjusted with a selection of critical variables. The model was developed using 
MATLAB software. 
2.1.1. Theory: Fick’s Diffusion 
Fick’s 1st law relates a particle’s diffusive flux to its concentration through the 
following relationship: 
ܬ ൌ െܦ ௗఃௗ௫	, (Equation 1) 
where J is the diffusive flux ቀ ௡௚௖௠మ∗௦ቁ, D is the diffusion coefficient, Φ is the drug 
concentration, and x is the linear position.  
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ௗ௫మ . (Equation 2) 
Under steady-state conditions, Fick’s 2nd law simplifies into the first law. With the 
exception of the leveling of concentration gradient during the initial burst of drug release, 
it is safe to assume that our device releases at steady-state conditions and this holds true, 
simplifying the diffusion model.  
2.1.2. Numerical Model 
2.1.2.1. Model Design 
Certain assumptions have to be made to consider the diffusion model valid. The first 
involves the design of the model. The model was constructed by simplifying the conduit 
in to three distinct regions: a uniform drug reservoir, the diffusion hole, and the inner 
conduit. In order to assume a one-directional diffusion, certain parameters must be met. 
First, the drug must be a homogenous solution, which means that the model ignores the 
effects of gravity and device orientation. Another assumption that is made in the model is 
that diffusion of drug occurs in a zero-velocity environment. Fluid motion can 
dramatically alter the performance of the device. The final crucial assumption that has to 
be made is that the nerve conduit remains a constant geometry device. The reservoir size 
cannot expand or collapse; if it did, it would produce fluid motion that would alter the 
release of drug. Additionally, because Fick’s diffusion is dependent on the cross-sectional 
and length geometries of diffusion regions, results can vary if the device walls expand or 
contract. 
Two different models were made: one to predict in vitro tests and one to predict in 
vivo behavior (APPENDIX). MATLAB software was used to produce the models. The 
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primary difference between the two is what dosage values are important in each case. The 
in vitro tests are measured in a receiver chamber, which collects the drug released from 
the system. At the time intervals where readings are collected, the receiver chambers are 
flushed and refilled with clean medium. This flushing process is accounted for in the 
model. The in vivo concentration of interest is the internal instantaneous concentration 
gradient within the guidance conduit. Under ideal conditions, this gradient will be linear 
within each diffusion region and is proportional to the diffusivity parameters of the 
sections. The model has the ability to correlate these two values to compare in vitro data 
with expected in vivo performance. The parameters that control this correlation will be 
discussed later. 
2.1.2.2. Convergence 
As with any numerical model, convergence of the results can affect the accuracy of 
the data. This model is a three-stage calculation that does not involve in-depth finite 
difference modelling or other methods that typically have high convergence thresholds. 
Because of this, we anticipated minimal errors and a convergence test was conducted to 
verify this. The convergence sensitivity was tested using 3, 10, and 100 iterations to 
validate whether the model avoided calculation errors. 
2.1.3. Delivery Parameters 
There are many parameters that affect the diffusion performance of drug delivery. 
One major advantage of this device is their independent behavior. First, the diffusion 
coefficient is determined by the specific drug being used and what medium it is diffusing 
through, with slight variations that depend on pressure and/or temperature. There are 
many theoretical calculations that can be used to determine this coefficient. One of the 
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simplest models is the Stokes-Einstein equation, where particles are assumed to be 
spherical and are diffusing through a viscous liquid continuum. This is a purely 
theoretical calculation that yields results that can vary by up to 40%. The Wilke-Chang 
equation relies on more empirical data and coefficients in its calculations, but it assumes 
that associated molecules behave as large-size molecules. The Scheibel equation 
calculates the diffusion coefficient by comparing molar volumes of particles and is 
accurate when the drug particle volume is smaller than the diffusion medium particle 
volume. While these theoretical calculations progressively become more accurate, the 
most accurate method of determining the coefficient of diffusion is to use experiments. 
Empirical measurements show the diffusion coefficient for NGF as 1.26 ൈ 10ି଺ 	௖௠మ௦௘௖  
when flowing through a buffered solution [18].  
2.1.3.1. Dimensional Analysis: Variable Dependencies 
For our nerve conduit, the diffusion rate depends on a specific set of constants. The 
first one is diffusion coefficient. Fick’s diffusion rate is linearly dependent on the drug 
diffusion coefficient and as a result, the rate of release will linearly change based on this 
value. The other factors that affect diffusion rate the most are the geometric parameters of 
the conduit. For each diffusion region, the cross-sectional area and length that it diffuses 
through affect the concentration gradient. As cross-sectional areas are decreased, the 
diffusion rate within each region is linearly decreased. Consequently, the conduit 
diameter and diffusion hole diameter will modify the diffusion rates in a quadratic 
manner.  As length of the inner conduit and wall thickness are increased, the diffusion 
rates through each of their regions also increase by a linear relationship. Finally, the 
amount of drug available does not affect the diffusion rate, but it does scale the actual 
16 
 
concentrations that are delivered over a set time. This value is determined by reservoir 
volume and the initial concentration of drug loaded into each device. This combination of 
adjustable variable inputs allows for fine tuning of the drug delivery parameters. 
Concentration measurements report the actual drug values accumulated in the 
receiver chamber or present in the conduit, depending on whether in vitro or in vivo tests 
are performed. These values essentially represent the integral of the diffusion rate and as 
a result, the measured concentration values are dependent on the rates of diffusion. For 
example, because initial concentration has a zeroth-order effect on diffusion rate, it has a 
first (linear) order effect on concentration dosage delivery values. While conduit length 
and wall thickness have a first-order effect on diffusion rate, they change concentration 
values in a quadratic relationship. The process of tuning diffusion rates to levels that will 
produce desired results is decided by modifying lesser-fixed variables to account for 
fixed variables. Diffusion hole size and initial concentration are the least-dependent 
variables that can be modified to compensate for the diffusion rate of each drug selected 
and the conduit size required. 
2.1.4. Modelling Results 
A convergence test was run to verify that the model produced data with minimal 
convergence errors and the results show that within 100 iterations, the model converges 
with <0.01% error (Figure 2.1). One factor that can multiply this error is the behavior for 
collection times to round the collection values to the closest time point. As a result, the 
actual model tests were run with two iterations each hour. Because the drug diffusion 
models were conducted using >700 iterations, the convergence error was declared 




Figure 2.1: Diffusion model convergence with varying iterations 
The diffusion model was used to determine parameters that would be used for each 
of the release kinetics tests proposed. Two primary diffusion targets were explored: 
maintaining a zeroth-order diffusion over 30 days and targeting a 60% release over 30 
days. Preliminary dextran release tests targeted a linear release of drug and while the 
release is never truly linear, it was found that by maintaining a 5% release over 30 days, 
the release rate would change by <10% over that time interval. 
By limiting diffusion to such a small range, safety concerns and flaws in 
manufacturing are amplified. First, in order to deliver the target concentrations, a 
significantly higher target concentration must be loaded into the conduits. In a worst-case 
scenario, if the device were to leak or burst within the body, the released drug could 
exceed toxicity levels. Additionally, as smaller diffusion holes are required to produce the 
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low diffusion ranges, in minor leaks and fluctuations based on manufacturing quality, 
device stability, and environmental variability can produce dramatically larger 
discrepancies than if a larger diffusion hole were used. With the in vitro tests, it is 
unknown whether the drug collected in the receiver chamber is released from the 
diffusion hole or if it is simply leaking from the device. If the diffusion hole can be made 
larger, the rate of diffusion through that proper channel becomes much larger than 
possible leaks and the data reliability and confidence increases. These reasons and the 
small differences between the diffusion hole and sealed devices in initial tests were 
enough to prompt a revised target diffusion range. 
A 60% release over 30 days was selected as a revised target diffusion. Minimizing 
safety risks, manufacturing errors, and environmental effects were major factors leading 
to this decision. However, another conclusion that made this selection feasible is the 
bioactive range of many of our drugs of interest. NGF has been shown to be bioactive 
and efficacious from 0.1ng/mL up to 20ng/mL; that range provides a significant delivery 
range for this nerve conduit. 
2.2. Manufacturing Methodology 
The nerve conduit was designed to be bioresorbable to avoid a secondary surgery for 
removal of the device following the healing process. As such, PLGA was selected as the 
material of choice because of its widespread usage in other bioresorbable medical 
devices. This polymer provides the resorbable properties necessary for the device, but by 
being a degradable material, it presents some unique challenges that traditional 
engineering materials would otherwise avoid, including a low glass transition 
temperature (40-60°C) and nontraditional mechanical properties. 
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2.2.1. Material Fabrication 
The bioresorbable guidance conduits were produced using 75/25 poly-lactic-
glycolic-acid (PLGA; 7525 DLG 7E, Evonik). Two liquefying methods were explored: 
melting and dissolving PLGA.  It was found that in melting the polymer, significant 
degradation had occurred in the material making it highly brittle and unworkable. The 
solvent method was selected for manufacturing devices and is detailed below. 
The stock 75/25 PLGA pellets were dissolved in acetone at a ratio of 10g PLGA to 
20mL acetone at 45°C. After manually stirring until a viscous solution formed, 6mL of 
ethanol was added to the solution. The ethanol serves as an emulsifier for the acetone to 
be displaced when the solution interacts with water. The solution was stirred at 180RPM 
on a stirring plate until visibly homogenous.  The solution was then used to fill glass 
molds. A flat petri dish was used as the mold to form 1.5mm thick sheets and glass tubing 
of various sizes were filled to construct the PLGA conduit tubing. 
2.2.2. Assembly Material 
The nerve conduits are composed of three primary pieces: an inner guidance conduit, 
outer drug reservoir conduit, and the end caps to seal the construction (Figure 2.2).  
 
Figure 2.2: Conduit assembly - inner conduit, outer conduit, and end caps 
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Glass tubing was used to mold the conduits. For conduits smaller than 3mm inner 
diameter, the following procedure was used. PLGA solution was suctioned into glass 
molds and then frozen at -20°C for 24 hours. Following that, they were left to cure for 12 
days at 23°C (room temperature). As the solvent evaporated from the solution, the 
surface tension from the mold naturally produced an even-thickness conduit within. The 
resulting thickness of the conduits is a factor that can be controlled based on the polymer-
solvent ratio. Following the curing process, the conduits were manually broken out of the 
glass molds and an ultrasonic bath was used to remove any remaining glass. 
For conduits larger than 3mm inner diameter, one additional processing step was 
taken to account for the decrease in surface tension forces due to the decreased surface 
area to volume ratio. Immediately following the suctioning of material into the conduits, 
any excess PLGA was allowed to drip out of the molds. The conduits were then placed 
vertically into a water bath and allowed to cure. The water bath quickly displaced the 
solvent and reduced deformations caused by gravity forces on the conduit. After 12 days, 
the conduits were released from the mold by using a matching ramrod to push them out.  
Conduit dimensions were determined based on studies for sciatic nerve repair for rat 
and mouse models. The following dimensions were used. The mouse inner conduits were 
molded to dimensions of 1.25mm OD and 1.067mm ID and then cut to a length of 13mm. 
The rat inner conduits were molded to dimensions of 2.4mm OD and 2mm ID and also 
cut to a length of 13mm. The outer conduits were the same for both devices, measuring 
4mm OD and 3mm ID and cut to a length of 7mm. 
End caps to join the conduits and form the drug reservoir were manufactured by 
forming a PLGA sheet. The same PLGA solution that was used for the conduits was 
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poured on to a glass petri dish and left on a 45°C hot plate. This heating process cures the 
sheet in a bottom-up process that minimizes wrinkling of the sheet as it expands and 
contracts. Following 4 hours on a hot plate, the sheet was submerged into water, allowing 
the emulsion process to remove any remaining solvent. The end caps were cut to size 
using a laser cutter. A properly sized end cap creates a slight press fit over the inner 
conduit and within the outer conduit. 
2.2.3. Conduit Assembly 
A solvent bonding process was adopted to assemble and seal the PLGA conduits. A 
solution consisting of 2g PLGA and 2mL acetone was mixed together to form a viscous 
solution. The solution was locally applied to join the end caps to the inner conduit. 
Following each application of solvent glue, the devices were placed into a water bath for 
24 hours to remove any residual solvents and return the assembly to a solid structural 
state. The resulting device is shown below in stage 1 of assembly (Figure 2.3). 
After stage 1, diffusion holes are then drilled into the devices using laser milling. 
Holes larger than 100μm were drilled using a VLS3.60 CO2 system (Universal Laser 
Systems) and holes smaller than 100μm were drilled using a MicroMaster KrF excimer 
laser system (Optec). The laser holes were stabilized by pulsing the laser multiple passes 
(40x). This process annealed the PLGA surrounding the diffusion holes and made them 
more stable once submersed into water. 
The final assembly step involved solvent welding the outer conduits to complete the 
drug reservoir. For the tests involved, both single and dual reservoir devices were built 
using this process. Once the outer conduit was attached, the devices were again placed in 




Figure 2.3: Dual reservoir conduit assembly (stage 1 top, completed bottom) 
2.2.4. Sterilization 
PLGA poses a few problems regarding sterilization. It is a reactive polymer that may 
break down from certain radiation or chemical sterilization processes. Additionally, the 
fragile co-polymer has a very low melting point and even lower glass transition 
temperature (40-60°C), eliminating many traditional sterilization methods like 
autoclaving. A study that ran sterilization tests involving ethanol, ethylene oxide (ETO), 
and plasma sterilization has shown that plasma sterilization yields the best results 
regarding PLGA degradation and device sterility [19]. Additional sterilization tests 
involving PLGA conduits with diffusion holes were performed. Samples were sterilized 
using 70% ethanol (n=42), ETO (n=46), and a Sterrad 100S plasma sterilization (n=50) 
process. The results indicated minimal hole deformation from the ethanol and Sterrad 
sterilization processes but a complete collapse of holes in ETO-sterilized samples. As a 
result, the Sterrad 100S system was chosen as the sterilization method for our PLGA 
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conduits due to minimal degradation and deformation and verified sterility. This test is 
discussed in further detail in section 3.2. 
An issue that resulted from the Sterrad sterilization process was the collapsing of 
conduit reservoirs on some devices. Due to the Sterrad process being processed under 
vacuum, as the system is reintroduced to atmospheric pressures, the pressure difference is 
enough to deform and permanently collapse the drug reservoirs. A final process of cutting 
a 2-3mm slit into the device wall was implemented to eliminate the collapsing of conduit 
reservoirs. 
2.3. Device Verification Methodology: Release Kinetics 
Verification tests were performed to ensure that the nerve conduits released drugs as 
expected. These in vitro tests were conducted by first loading each conduit reservoir with 
their respective drugs. For the tests specified above, they were loaded through the conduit 
slits that were cut to balance the reservoir pressures for reliable sterilization. Following 
loading, the devices are resealed using the same PLGA glue used during assembly. They 
are then attached to the side wall of their respective receiver chambers where tests are 
conducted. A 7mL transport tube was used as the receiver chamber for all of the tests 
conducted. PDMS was used to attach the devices to the wall in a location that would still 
allow for the devices to be fully submersed after the receiver chambers were filled with 
their test medium (either phosphate-buffered saline or growth media). 
Once these tests were set up, samples were collected from the receiver chamber at 
determined time frames. Once the fluid was collected, the receiver chamber was flushed 
and new medium was added to the chamber. This simulated the body’s natural ability to 
flush away drug once it was released from the devices. The in vitro tests were designed to 
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mimic the in vivo conditions of the conduits within the body. The flushing process of the 
receiver chamber imitates the body’s natural process of fluid transfer around the 
implanted device which could be modeled as an instantaneous flushing of any drug 
leaked out of the device.  
To prevent degradation, the samples were stored at -20°C for the dextran samples 
and -80°C for the NGF samples. Dextran samples were also stored in dark conditions to 
prevent fluorescent breakdown. Once enough samples were collected, they were loaded 
into 96 well plates and read using a fluorescent plate reader for dextran and 
corresponding enzyme-linked immunosorbent assay (ELISA) kits for NGF (rat betaNGF 
ELISA kit, Abcam). Each plate was loaded with a corresponding standard curve to 
correlate its fluorescence with a known concentration value. 
The release data were processed by constructing a cumulative drug release over the 
entire test duration and plotted in correlation with the expected modelling results. 
Conversion between fluorescence values and concentration was done with a best fit using 
the standards for each plate. A percentage release was calculated by dividing the known 
released drug mass by the total drug injected into each device. Excel and MATLAB 
software was used to perform these calculations. 
4 primary tests were performed:  
1. An initial dextran release test using approximate zeroth-order release 
2. A dextran release optimization test to release ~60% of the total drug over a 30-
day interval 
3. An NGF release test conducted in a simulated in vivo environment 
4. A dextran release tests conducted in a simulated in vivo environment 
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2.3.1. Dual Conduit Zeroth-Order Release Test 
The initial release test was conducted using dual mouse conduits in order to show 
that extended release was possible from the PLGA conduits. Initial tests were done with 
dextran, which is simpler and less expensive to measure, than the intended drugs.  The 
dextran being released had two different fluorescent tags: Fluorescein (D1821, 
10,000MW, Molecular Probes) and Texas Red (D1863, 10,000MW, Molecular Probes). 
These fluorescent dextrans were used because of their similar molecular weights and 
diffusion coefficients to one of the target drugs, NGF. These specific dextrans were 
chosen because their excitation and emission wavelengths occurred at different ranges 
(Fluorescein – Ex. 494 Em. 521; Texas Red – Ex. 595 Em. 615).  
Along with verifying manufacturing techniques, this test was conducted with a 3% 
drug release over 30 days to demonstrate and measure steady chemical release. This 
design parameter was chosen to drive as close of a linear release as possible. By limiting 
the amount of active drug and increasing the starting concentration, the release model 
predicted a nearly zeroth-order release from these devices over 30 days. 
This test was conducted using seven devices: Three devices with one 15μm diameter 
hole per drug reservoir (n=6) and four sealed devices that had no diffusion holes present. 
The sealed devices were used to verify assembly reliability. A negative control (device 
with no drug) was also used in the experiment. The drug reservoirs were approximately 
20μL each and were loaded with a starting concentration of 50mg/mL of dextran. These 
tests were conducted at room temperature (~21°C) under nonsterile conditions. The 
devices were not sterilized before testing. Phosphate-buffered saline (PBS) was chosen as 
the receiver chamber medium and dilution fluid for all dextran testing. 
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2.3.2. Single-Conduit 60% over 30 Days Dextran Release Test 
Following the results from the initial release test, additional refinement of delivery 
targets was determined. While releasing a constant delivery of drug from the conduit is 
the ideal, the bioactivity and efficacy of NGF on nerve cells spans a significant range. In 
order to more properly measure if the devices were releasing as expected, the release 
target was increased from a 3% release over 30 days to a 60% release over 30 days. 
The conduits used to perform this test were designed to surgically reattach a rat’s 
sciatic nerve and were constructed with a larger inner conduit than the mouse conduits. 
Single reservoir conduits were chosen for this test in order to minimize manufacturing 
variability and error. The drug reservoirs held approximately 20μL of drug and were 
loaded with an initial concentration of 10mg/mL of dextran (Fluorescein, D1821). The 
test was conducted using eight devices: six devices with one 130μm diameter hole and 
two sealed devices with no diffusion holes. A negative control with no drug was also 
used. These tests were conducted at room temperature (~21°C) under nonsterile 
conditions. The devices were not sterilized before testing. 
2.3.3. Single Conduit NGF Release Test 
The next level of progression with in vitro testing was simulating an in vivo 
environment. These devices were sterilized using the Sterrad 100S process and the 
diffusion tests were performed in an incubator at 37°C. The tests were performed using 
single reservoir rat conduits. Dextran was used through the previous tests due to its 
similar diffusion coefficient to NGF, but simulating actual NGF release is essential as 
proof of concept before in vivo testing. 
This test was conducted using nine devices: three devices with one 130μm diameter 
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hole using a starting concentration of 0.025mg/mL NGF, three devices with one 130μm 
diameter hole using a starting concentration of 0.05mg/mL, and three sealed devices with 
no diffusion holes using a starting concentration of 0.05mg/mL.  In addition to testing 
NGF release kinetics, two varying initial concentrations were tested to verify linear 
release scaling based on the amount of drug loaded. A negative control with no drug was 
also used.  
These tests were conducted in an incubator (37°C) under sterile conditions. Device 
loading and sealing was done in a bio-sterile hood and the receiver chamber medium 
consisted of a media/fetal bovine serum (FBS) matric containing growth media (DMEM 
F12, HyClone), 10% FBS (HyClone), and 1% antibiotic/antimycotic solution (HyClone). 
The NGF was diluted to the proper initial concentrations also using this media matrix. 
For in vitro testing, the range of delivery was selected based on the accurate range of the 
ELISA kits used to read the data.  
2.3.4. Single Conduit Dextran Release Test at Simulated in vivo Conditions 
Another dextran test was conducted to test the devices in sterile and incubation 
conditions. Dextran results are simpler to read and it is a cheaper alternative to NGF and 
also poses no risk of contamination, justifying performing additional tests with this 
approach. This test used the same 60% release target over 30 days as the previous dextran 
test. Single reservoir rat conduits were chosen for this test and they were sterilized using 
the 100S system. Fluorescein (D1821) was used as the release chemical and the receiver 
chambers were filled with 3mL PBS. The devices were loaded and tested under sterile 
conditions and the tests were conducted in an incubator (37°C). Eight devices were used 
for this test: five devices with 130μm holes were tested along with three sealed devices. 
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All the devices were loaded 20μL with an initial concentration of 5mg/mL. The tests 
were conducted out to 21 days. 
2.4. Release Results and Discussion 
2.4.1. Dual Conduit Zeroth-Order Release Test 
Figure 2.4 shows the results from a 7-day collection. The release plot shows that the 
conduits were able to release drug consistently for an extended period of time. However, 
the sealed data also showed that it was hard to distinguish whether these devices were 
leaking from improper device sealing or if the drug was actually diffusing through the 
release holes, as the release from all conduits was above the predicted level. One 
important observation was that with each of these 7 devices, the reservoir assembly was 
successful in that 6 of the 7 reservoirs avoided mixing. This validated the construction 
and sealing techniques of the device. 
 
 

















Diffusion Model 15um Diffusion Hole (n=6) Sealed Devices (n=8)
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2.4.2. Single-Conduit 60% over 30 Days Dextran Release Test 
Figure 2.5 shows the results over a 43-day collection. The anticipated results from 
the diffusion model are shown in red with a ±40% error range shown. Further tests 
discussed later verified that this initial error range falls within the acceptable bioactivity 
levels where NGF has a positive effect on nerve growth. The results show two favorable 
conclusions: first, the sealed devices effectively released negligible material, verifying 
the construction of the conduit and adding confidence that the drug collected from the 
receiver chamber was actually being released through the diffusion holes in the inner 
conduit. Second, the 130μm diffusion hole devices match very closely with the diffusion 
model over the entire collection period. The standard deviation of the six test devices fits 
within the 40% error range and conclusions can be drawn that under room temperature 
and unsterilized conditions, the nerve conduits deliver drug as expected. 
 
 

















Diffusion Model 130um Diffusion Hole (n=6) Sealed (n=2)
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2.4.3. Single Conduit NGF Release Test 
Figure 2.6 represents the data from the NGF release tests superimposed over its 
diffusion model. Neither of the test groups fell within the targeted range, but they were 
considerably higher than the sealed test group. However, all six devices released NGF at 
similar rates with little deviation, showing significant improvements in manufacturing 
reliability. This test was designed to release over a 30-day span, but the samples 
contaminated after 3 days and the test was conducted with PBS as the receiver medium 
after 8 days. A possible factor that may contribute to results that do not match release 
models is the acidity of the solution following contamination. NGF has been shown to 
have increased degradation under higher temperatures and lower pH levels [20]. While 
the exact mechanism for NGF degradation was not known, it is understood that between 
interaction with the contaminated sample and the change in acidity in the test chamber 
led to readings well below expectations. 
 
 

















130um @.05mg/ml (n=3) 130um @.025mg/ml (n=3)
Sealed Devices (n=3) Diffusion Model
31 
 
Even with the results likely altered due to contamination, there were still solid 
conclusions to be made from this test. Figure 2.7 shows the cumulative concentration 
release from the devices over time. In comparing the 0.025mg/mL and 0.05mg/mL 
starting concentrations of the two test groups, it is shown that the release from the 0.05 
mg/mL devices closely resembles a doubling when compared to the 0.025mg/mL group. 
This verifies the ability to linearly scale the drug release range by varying the initial 
loaded concentration of drug. As a result, percent release can be viewed analogously to 
the actual amount of drug being released. This understanding is crucial in comparing drug 
release results between varying drugs because of different reading ranges for each of 
them. It is also important in being able to run optimized in vitro tests and then use those 
results to directly convert the results to an effective in vivo bioactive range. 
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One final observation from this test was increased polymer degradation from these 
contaminated devices. The PLGA devices that contaminated in this test swelled at a much 
quicker rate than devices that did not contaminate and also began disintegrating before 
the test was completed. It is still unknown whether the acidic conditions or the enzyme-
rich environment played a larger role in this degradation, but it supports claims from 
other literature that degradation rate is affected by the PLGA solution environment. 
Actual degradation rates in vitro and in vivo do not align directly with PLGA’s 
degradation due to hydrolysis and further tests must be performed to avoid problems with 
premature device degradation when in vivo tests are conducted in the future. 
2.4.4. Single Conduit Dextran Release Test at Simulated in vivo Conditions 
Figure 2.8 shows the results of the dextran release tests run in an incubator and 
sterile conditions. Drug release from the conduit appears to initially outpace the diffusion 
model and then slowly taper off after the first two days. It is to be noted that with the 
exception of one of the sealed devices that leaked and was considered an outlier, the 
results from both the sealed group and the diffusion hole group produced very small 
deviations. It is still unknown what is directly causing the variation in diffusion rate, but 
three hypotheses can be made. While the diffusion coefficient only changes by a small 
amount as the temperature is raised from 21°C to 37°C when it is placed in the incubator, 
the effects of temperature on the PLGA conduits is still unknown. It is possible that the 
swelling of the conduit material causes pressurization of the reservoirs and the initial 
drug burst is caused by that. Another hypothesis is that the diffusion holes were not 





Figure 2.8: Dextran diffusion test conducted in in vivo environment 
The final possible explanation can work in conjunction with the previous two. There 
are two main factors that can contribute to a different release rate in our conduits: release 
geometries and effective drug volume. While previous dextran tests at room temperature 
fell within our expected release rates, it is possible that at these elevated temperatures, 
some of the drug is becoming absorbed by the conduit and the amount of drug that is in 
the reservoir is reduced, providing a lower working volume. While it is seen that the 
diffusion rates do not match their ideals, the results still show promise by delivering a 
device that can still release drug within a bioactive range over 20 days. The factors that 
were affecting the drug release rates were universal, and additional tests would need to be 























3. SUPPORT MATERIALS 
This section is dedicated to materials that were support tests leading towards 
successful conduit diffusion. Many of the tests performed helped characterize PLGA and 
its untraditional mechanical behaviors that are negligible in many other engineering 
materials. PLGA is a fragile co-polymer that has very low melting point and even lower 
glass transition temperature (40-60°C). Consequently, a lot of processing techniques that 
are available for more stable materials are not an option for the polymer. Two tests that 
will be discussed involve the processing to produce diffusion holes that showed stability 
through the sterilization process as well as at in vivo conditions. 
3.1. Diffusion Hole Stability 
Results from Dextran tests ran at incubation temperatures showed a considerable 
drop-off in release after two days. It was assumed that the conduit diffusion holes were 
collapsing during that initial submersion period. PLGA is known to absorb water and can 
swell in size. Following testing results that showed variations to the diffusion models, 
several preliminary tests were conducted at 37°C and images were taken of the diffusion 
holes after certain time intervals. The device holes shrunk considerably after 24 hours 
(Figure 3.1). Following this initial swelling period, they appeared to stabilize. This 




Figure 3.1: Diffusion hole shrinkage at 37°C a. after drilling (169μm diameter) b. 24 
hours after being submersed in PBS (78μm diameter) c. 48 hours after being submersed 
in PBS (108μm diameter) 
 
Diffusion was chosen as the primary drug delivery mechanism due to its simplicity 
and predictability. PLGA’s mechanical properties, like most polymers, can be modified 
through processing the material and modifying its crosslinking behavior. Since our holes 
are drilled using laser etching, it is possible that residual stresses build around the hole 
and the material does not get cut away. Instead, it recedes from the hole and as the 
conduit is placed back into incubation conditions and water, those stresses are relieved 
and the hole closes on itself. 
As PLGA is exposed to elevated temperatures above its glass transition temperature, 
polymer chains form crosslinks. On a mechanical scale, that results in a much stiffer 
material. While the conduits as a whole need to maintain some level of suppleness in 
order to suture their ends and perform histology tests, overall drug diffusion seems to 
benefit from a more stable device. Local cross-linking at key areas such as the diffusion 
hole was hypothesized to stabilize diffusion results. A series of tests to stabilize the holes 
were performed on the holes including laser annealing, heat annealing, and plasma cross-




3.1.1. Hole Processing 
3.1.1.1. Laser Annealing 
The laser annealing process involved using the laser cutter to locally heat the PLGA 
conduit around the diffusion hole. This was done by running multiple low-powered 
passes over the diffusion hole. When high power was used, the diffusion hole often 
became too big due to the residual heat but by running a low intensity 40x burst, the holes 
cut to similar geometries as desired. After these holes were drilled, the devices were 
submersed into water and placed in an incubator. Figure 3.2 shows images of these holes 
at time intervals of 0, 8, 24, and 72 hours after submersion. A total of 15 devices were 
tested using this procedure. Minimal shrinkage over this duration is observed. 
 
 
Figure 3.2: Laser-annealed hole after submersed in water at 37°C for a. 0 hours (200μm) 
b. 8 hours (204μm) c. 24 hours (210μm) d. 72 hours (214μm) 
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3.1.1.2. Heat Annealing 
The heat annealing process was performed by taking a conduit with a previously 
drilled diffusion hole and heating it at 60°C for 30 minutes. In comparison to the laser 
annealing process, this treatment formed crosslinks within the entire conduit. It was 
unknown whether this would adversely affect the performance of the conduit so unless 
significant improvements were shown over the localized laser process, this process would 
be chosen as a secondary option. Following this, the conduit was tested for shrinkage. 
The devices were submersed into water and placed in an incubator. Figure 3.3 shows 
images of these holes at time intervals of 0, 8, 24, and 72 hours after submersion. A total 




Figure 3.3: Heat-annealed hole after submersed in water at 37°C for a. 0 hours (207μm) 
b. 8 hours (212μm) c. 24 hours (162μm) d. 72 hours (191μm) 
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3.1.1.3. Plasma Crosslinking 
The plasma crosslinking process was performed by taking a conduit with a 
previously drilled diffusion hole and exposing it to a corona plasma burst for 30 seconds. 
Plasma is known to break and rebuild crosslinks within polymers. By exposing the 
conduit to an extended plasma burst, these crosslinks would form at an accelerated rate 
and the rigidity of the polymer was expected to increase. The conduit was then tested for 
shrinkage. The devices were submersed into water and placed in an incubator. Figure 3.4 
shows images of these holes at time intervals of 0, 8, 24, and 72 hours after submersion. 
A total of 2 devices were tested using this procedure. Minimal shrinkage over this 
duration is observed. 
 
 
Figure 3.4: Plasma-processed hole after submersed in water at 37°C for a. 0 hours 
(204μm) b. 8 hours (206μm) c. 24 hours (182μm) d. 72 hours (205μm) 
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3.1.1.4. Hole Punching 
It is assumed that the diffusion holes shrunk so aggressively because no material is 
actually removed during the laser drilling process. Instead, it melts away from the drill 
site and the residual stresses force the hole shut as the conduit is placed into testing 
conditions. Instead of using a laser to drill the diffusion holes, a 30-gage wire was 
sharpened and used to punch a diffusion hole. The dimensions of a 30-gage wire are 
.159mm ID and .311mm OD. The conduit was then tested for shrinkage. The devices 
were submersed into water and placed in an incubator. Figure 3.5 shows images of these 
holes at time intervals of 0, 8, 24, and 72 hours after submersion. One device was tested 
using this procedure. After 8 hours, the hole appears to shrink considerably (from 244μm 
to 131μm) but the hole maintains its geometry afterwards.  
 
 
Figure 3.5: Punched hole after submersed in water at 37°C for a. 0 hours (244μm) b. 8 
hours (131μm) c. 24 hours (143μm) d. 72 hours (152μm) 
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3.1.2. Hole Stabilization Conclusions 
The results from these tests show that all of the processing techniques yield more 
favorable results than unprocessed conduits. Both annealing processes and the plasma 
cross-linking process seemed to prevent the holes from shrinking or swelling as they did 
when unprocessed. The punched hole appears to show the effect of both a cored and 
stretched hole during the punching process. Initially, the hole resembles a diameter closer 
to that of the punch outer diameter. After the conduit was submersed for 8 hours, the 
region that could have been stretched out over the punch taper appears to swell back and 
the hole shrinks down to a size comparable to the punch inner diameter. While no 
additional tests were performed with this manufacturing method because it would be 
harder to perform than the other methods tested on a large scale, it proves to be a viable 
backup method and produces more circular holes than laser drilling. Laser annealing was 
chosen as the hole processing method mostly because it only alters the material on a 
localized area near the hole instead of over the entire inner conduit. 
3.2. Sterilization 
PLGA poses a few problems regarding sterilization. It is a reactive polymer that may 
break down from certain radiation or chemical sterilization processes. Because PLGA has 
a relatively low glass transition temperature, many traditional sterilization methods like 
autoclaving are not an option. Previously, our devices showed considerable shrinkage 
when sterilizing devices, leading to inconsistencies in diffusion properties caused by 
varying drug reservoir volumes as well as changing diffusion hole sizes. Some 
sterilization techniques also have significantly changed our materials and lead to 
hardened devices and degradation in the polymeric structure. This poses a problem when 
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implanting the devices, making them hard to manipulate and suture into place. 
Previous literature suggested that three sterilization methods produced more stable 
and repeatable results with 85/15 PLGA: plasma sterilization, ethylene oxide (ETO), and 
ethanol [19]. Their tests indicated that plasma set at 100% power typically shrunk PLGA 
by up to 50%. However, plasma set at 50% power had no effect on geometric integrity. 
ETO was found to shrink PLGA by ~60% and also reduced its molecular weight 
significantly from polymer degradation. When soaking PLGA in 70% ethanol, their tests 
indicated no significant geometric effects or polymer degradation; however, the 
biocompatibility tests revealed poor sterilization results. The goal in the following 
sterilization tests was to determine the best technique to produce repeatable sterilized 
conduit devices while limiting PLGA degradation and preserving the mechanical 
integrity of the conduits. 
The following methods were tested for sterilization: 
 Sterrad Plasma Sterilization (ASP Sterrad 100S System): (50% power) 
 Ethylene Oxide 
 70% Ethanol: PLGA conduits were soaked in ethanol for 30 minutes and then 
promptly removed. Following this, they were bathed in water for 6 hours to 
displace the solvent and re-harden the polymer. 
Each test used four conduits (n=4) with each one containing eight diffusion holes 
(~120-150 µm diameter). These holes were drilled using a laser and each one had a small 
inward taper of ~10° from the residual laser energy. Two of the conduits were sterilized 
while fixed on a needle to retain cylindrical structure while the other two were sterilized 




For these devices, the holes (n=36) remained approximately the same size (<20% 
change). This was in contrast to our sterilization results using a Sterrad 100NX procedure 
at 90% power. Under those test conditions, the PLGA conduits shrunk and deformed by 
up to 50% volume. For the Sterrad 100S system at 50% power, the conduits maintained 
their geometric integrity (Figure 3.6). They also retained a similar hardness to their 
presterilization conditions. This was important for preserving the ability to suture the 
conduits to the nerve endings. 
3.2.2. Ethylene Oxide 
Following ETO sterilization, all of the devices significantly deformed from their 
original cylindrical shapes and all of the diffusion holes fused (Figure 3.7). Each conduit 
also significantly hardened from the process. The PLGA conduits are highly sensitive to 
temperature and the ETO process is run at 60°C. However, the chemical sensitivity of the 
polymer to the ETO process is unknown. Regardless, from these observations, it was 
concluded that the ETO process we used was too aggressive and unstable for 75/25 
PLGA conduits. 
3.2.3. Ethanol 
The conduits sterilized with ethanol were slightly larger poststerilization and the 
diffusion holes expanded slightly (~25%) at their bottom tapers (Figure 3.8). However, a 
major consideration for avoiding this process is because of its nontraditional nature. It 
would be hard to show the sterilization justification of these conduits. In addition, there 
would be extensive training required to ensure that the sterilization procedure was done 




Figure 3.6: Sterrad presterilization hole (176/102µm, left) and poststerilization hole 
(156/125µm, right) 
 
Figure 3.7: Ethylene oxide poststerilization deformation (left) and sealed hole (right) 
 




3.2.4. Sterilization Justification 
Based on the results of these tests, Sterrad sterilization using the 100S system at 50% 
power minimized negative effects on the diffusion holes. Degradation, shrinkage, and 
deformity caused by ETO sterilization eliminate its viability for PLGA conduits. Ethanol 
sterilization is a viable option regarding polymeric degradation and geometric 
consistency but it is unknown whether this method can sufficiently sterilize the devices 
for implantation. Because there is little deformation caused by the Sterrad system, holes 
can consistently be drilled and diffusion tests will have more reliability than the other 
sterilization methods. 
One final issue that resulted from the Sterrad sterilization process was the collapsing 
of conduit reservoirs. It is theorized that due to the Sterrad process being processed under 
vacuum, as the system is reintroduced to atmospheric pressures, the pressure difference is 
enough to deform and permanently collapse the drug reservoirs. In order to avoid this, a 
final process of cutting a slit into the device wall was implemented to eliminate the 








The results of the in vitro drug release tests offer positive insight into the reliability 
and function of our nerve conduits. The following section includes conclusions and 
contributions that were made through the course of this project and also explores future 
direction for the project. 
4.1. Conclusions 
This project started in continuation to previous work on nerve conduits. The goal of 
successfully facilitating nerve regeneration through a guidance conduit was further 
developed. A revised diffusion model was generated to predict diffusion rate based on 
critical variables. The PLGA manufacturing process was refined to produce more 
consistent conduits. These bioresorbable conduits were tested to verify diffusion by 
running bench tests and comparing drug release results to numerical models.  
The first of these tests was conducted at room temperature with dextran release drug 
and verified that sustained drug release was possible. The second diffusion test worked 
from the first test’s results and it was decided that increasing the target diffusion rate 
would result in more consistent drug release and minimize error. This test was also 
performed at room temperature with nonsterilized devices. The results verified consistent 
release very close to the predicted values. A third diffusion test was conducted to test a 
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bioactive release of NGF from the devices as well as sterilized devices at body 
temperature. This test resulted in contaminated samples and a revised protocol was 
developed to eliminate this risk in future bench tests. However, functional data were 
produced from this test. The sealed devices maintained their integrity and results showed 
a linear relationship between starting concentration and drug released. The final test was 
conducted using dextran release and the tests were performed at in vivo conditions 
(sterile, body temperature). While the drug diffusion followed a different release rate than 
expected, they still remained in the bioactive range and the release data produced the 
smallest standard deviations to date. Further investigation is required to determine the 
cause of increased initial drug burst but possible causes include pressurized devices due 
to PLGA shrinkage. Additionally, a reduced hole size from the polymer swelling could 
have reduced the diffusion over time. 
4.1.1. Drug Release 
 Diffusion of drug through our conduits can be tuned by both linear scaling and 
diffusion rate.  
o Diffusion rate is dependent on the hole size, reservoir size, wall thickness, and 
other conduit geometries. 
o Linear scaling can be achieved by modifying the initial concentration of drug 
loaded. 
 Multireservoir conduits can be fabricated and drug can be released over a 30-day 
span. 
 At room temperature conditions, kinetics from the devices fell within the bioactive 
range of drug released. 
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 Drug release rates are independent of loading concentrations; consequently, actual 
dosage rates can be linearly scaled to any level. 
4.1.2. Device Structure 
 In situations where contamination was present, PLGA devices degraded at an 
accelerated rate 
o This suggests that hydrolysis is accelerated in these conditions or there are 
other mechanisms leading to the polymer degradation outside of hydrolysis 
 Sterilization of the PLGA conduits can be achieved using a Sterrad plasma system, 
yielding sterile devices that maintain their structural integrity. 
 PLGA naturally swells when exposed to water for extended periods and additional 
processing must be performed to prevent geometric deformations. 




 Developed release model that can predict the drug release rate from our nerve 
conduits for any reservoir size, diffusion hole size, initial drug concentration, conduit 
size or geometry, number of drug reservoirs, or drug diffusion coefficient. The 
models can accommodate time-dependent geometric variances as well. 
 Developed correlation models between in vitro collection concentrations and the 
concentration gradient of drug within the inner conduit that depicts the instantaneous 
concentration that cells react with in vivo. 
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4.2.2. PLGA Processing and Manufacturing 
 Developed system to track individual devices through their manufacturing process in 
batches up to 50 devices. 
 Constructed jig fixture to aid with assembly of devices and drug loading. 
 Developed solvent welding techniques to seal PLGA devices. 
 Developed and optimized diffusion hole stabilization techniques. 
 Determined proper techniques to prevent reservoir collapse during the Sterrad 
sterilization process. 
 Developed drug loading techniques to fill and seal drug reservoirs 
4.2.3. Release Kinetics 
 Developed proper sterile condition protocols for loading and collecting in vitro test 
samples. 
 Developed postprocessing techniques to convert fluorescent readings into 
concentration values for Dextran and NGF. 
 Optimized in vitro collection protocol to minimize disruption in diffusion. 
4.3. Future Work 
Future work on this project will include completion of in vivo tests that show proper 
functional recovery on sciatic nerve lesions in mice and rat implantations. The first of 
these studies will be performed using a comparison of autografts (n=16), nerve conduits 
loaded with NGF (n=16), and nerve conduits without any drug delivery (n=16). 
These animal tests will be essential to validating device performance in bodily 
conditions. Functional recovery is the ultimate goal of the nerve conduits and walking 
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tracks and comparison to autologous grafts will serve as a benchmark to determine the 
efficacy of the device. In addition, histological tests will be used to observe the growth 
patterns of the nerve endings through the guidance conduit. The integrity of the conduit is 
essential to extended drug diffusion and an in vivo test will determine if the PLGA 
devices can withstand the environmental forces as well as the fluidic and enzyme 
conditions found in a body.  
The latter half of testing through this thesis was done using single rat conduits; 
comparable results will have to be generated using dual release mouse conduits. Such 
work will require miniaturization of the devices. The duration of diffusion is controlled 
by two factors: diffusion rate and total amount of drug available. As the drug volume 
shrinks, a slower diffusion rate is required to prolong diffusion over an equivalent time 
period. As a result, diffusion hole drilling techniques that result in more stable holes will 
have to be developed and optimized.  
Another problem that we encountered during testing at elevated temperatures is 
instability of PLGA. Further tests to reinforce the bulk structure and the diffusion holes 
will be conducted, but if they cannot be stabilized, the advantages of a diffusion release 
will be negated and alternative materials will have to be explored. Some materials that we 
know retain longer half-lives and could potentially withstand in vivo conditions include 
PGA and collagen. In parallel to this research, it would be valuable to conduct tests with 
nondegradable devices that are known to maintain their structural stability to further 
confirm the diffusion models and design of the drug release conduit while avoiding issues 
with PLGA. Once the diffusion models and tests are confirmed and optimized, material 




 The tests discussed above will provide more concrete data on the performance of 
the devices. Building a nondegradable device will ensure the design is functional and will 
allow us to optimize the diffusion model and its constants. There are additional polymer-
stabilizing processes that still need to be tested to determine if PLGA is a viable diffusion 
conduit material. If it proves too difficult to produce devices that perform as desired in 
the body, other more stable degradable materials such as PGA or collagen can be tested. 
These additional studies will drive forward the development of a successful drug delivery 






DIFFUSION MODEL – MATLAB CODE 
 
Fick’s Diffusion Function 





% Scott Ho 
% Created: 5/8/14 
% 
% Function to perform diffusion calculations according to Fick's Law 




%       Select proper model [model_select, 0 (receiver) or 1 (stump)] 
%       Diffusion coefficient [D_coeff, cm^2/s] 
%       Reservoir initial concentration [C_reservoir, mg/ml] 
%       Thickness of inner conduit [t_IC, mm] 
%       Length of inner conduit [L_IC, mm] 
%       Initial and final times [time_i, time_f, hr] 
%       Number of iterations [iterations, integer] 
%       Collection times [collections, days] 
%       Reservoir volume [V_reservoir, ml] 
%       Diffusion Hole diameter [diam_hole, um] 
%       Number of Diffusion Holes [hole_count, integer] 
%       Inner Conduit diameter [diam_IC, mm] 
%       Receiver Chamber Volume [V_receiver, ml] 
%       Length of nerve stump [L_stump, mm] 
% Outputs: 
%       Array of total concentration over time [C_out_all, ng/ml] 
%       Receiver concentration values at collection times 
[C_out_collections, mg/ml] 
%       Time at collection [t_collections, sec] 
%       Instantaneous concentration at the diffusion hole exit 
[C_conduit, mg/ml] 
%       Instantaneous drug mass at the diffusion hole exit [M_conduit, 
mg] 





% Assumptions made for the following model: linear diffusion, steady-
state 
% (no velocity gradient), D taken from literature, neglecting edge 
effects 
% and PLGA interaction, well-mixed homogeneous fluid. 
% 
% 
% Receiver chamber - model_select is 0 
% Nerve Stump/In-vivo - model_select is 1 
% 
% Receiver chamber model: Concentrations at the receiver chamber are 
summed 
% together and continue to collect until the chamber is flushed 
% 
% Stump model: Inner conduit instantaneous concentration gradient is 
% outputted and correlated to the equivalent amount of drug diffused 
from 
% the conduit 
  
function [C_out_all, C_out_collections, C_cumulative, t_collections, 
C_conduit,... 
    M_conduit, M_out_all] = Ficks_Diffusion(model_select, D_coeff,... 
    C_reservoir, t_IC, L_IC, time_i, time_f, iterations, 
collections,... 
    V_reservoir, diam_hole, hole_count, diam_IC, V_receiver, L_stump) 
  
  
%%% Unit Conversions to standard units, model parameter, and 
dimensional 
%%% values for calculation 
concentration = C_reservoir;                        %mg/ml 
mass_reservoir = concentration*V_reservoir;         %mg 
%Set diffusion lengths according to device and setup geometries 
L12 = t_IC/10;                      %convert mm to cm 
if model_select == 0 
    L23 = L_IC/2/10;                %convert mm to cm 
    L34 = 0; 
else 
    L23 = (L_IC/2 - L_stump)/10;    %convert mm to cm 
    L34 = (L_stump)/10;             %convert mm to cm 
end 
time_i = time_i * 60*60;            %convert hrs to sec 
time_f = time_f * 60*60;            %convert hrs to sec 
time = linspace(time_i, time_f, iterations);    %time array in sec 
delta_t = time(2)-time(1); 
%map collection times to their proper iteration times in seconds 
for map = 1:size(collections,2) 
    collections(map) = collections(map)*24*60*60;   %convert days to 
seconds 
    [~, index] = min(abs(time-collections(map))); 
    collections(map) = time(index); 
end 
  
diam_hole = diam_hole*1e-4;         %convert um to cm 
diam_IC = diam_IC/10;               %convert mm to cm 
A12 = pi*(diam_hole/2)^2*hole_count;%cm^2 
A23 = pi*(diam_IC/2)^2;             %cm^2 
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V1 = V_reservoir;                   %cm^3,ml 
% V12 = A12*t_IC;                     %cm^3,ml 
% V23 = A23*L23;                      %cm^3,ml 
V3 = V_receiver;                    %cm^3,ml 





%initialize concentration/mass and flux arrays 
M1 = mass_reservoir*ones(size(time)); 
M2 = zeros(size(time)); 
M3 = zeros(size(time)); 
M_out_all = zeros(size(time)); 
M_out_collections = zeros(size(collections)); 
JM1 = zeros(size(time)); 
JM2 = zeros(size(time)); 
C1 = concentration*ones(size(time)); 
C2 = zeros(size(time)); 
C3 = zeros(size(time)); 
C_out_all = zeros(size(time)); 
C_out_collections = zeros(size(collections)); 
C_cumulative = zeros(size(collections)); 
J1 = zeros(size(time)); 
J2 = zeros(size(time)); 
  
t_collections = zeros(size(collections)); 
collection_count = 1; 
  
%Loop through time iterations 
for step = 1:size(time,2) 
     
    %%%%%%%%%%code for receiver chamber model%%%%%%%%%% 
    if model_select == 0 
%         syms conc1 conc2 conc3 
%         C2_eq(conc1,conc3) = solve(-D_coeff*(conc1-conc2)/L12*A12 == 
-D_coeff*(conc2-conc3)/L23*A23, conc2); 
%         C2(step) = C2_eq(C1(step),C3(step)); 
        %simplified C2 equation 
        C2(step) = (A12*L23*C1(step) + A23*L12*C3(step))/(A12*L23 + 
A23*L12); 
        M2(step) = (A12*L23*M1(step) + A23*L12*M3(step))/(A12*L23 + 
A23*L12); 
        J1(step) = -D_coeff*(C1(step)-C2(step))/L12; 
        JM1(step) = -D_coeff*(M1(step)-M2(step))/L12; 
        J2(step) = -D_coeff*(C2(step)-C3(step))/L23; 
        JM2(step) = -D_coeff*(M2(step)-M3(step))/L23; 
         
        %Flush check: if receiver chamber is sunk, reset receiver 
        %concentration to 0. Models flushing of samples. 
        for count = 1:size(collections,2) 
            if collections(count) == time(step) 
                %output receiver chamber concentration at collection 
times 
                C_out_collections(collection_count) = C3(step); 
                M_out_collections(collection_count) = M3(step); 
                t_collections(collection_count) = time(step); 
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                collection_count = collection_count + 1; 
                C3(step) = 0; 
                M3(step) = 0; 
            end 
        end 
         
        C1(step+1) = C1(step) + J1(step)*A12*delta_t/V1; 
        M1(step+1) = M1(step) + JM1(step)*A12*delta_t/V1; 
        C3(step+1) = C3(step) - J2(step)*A23*delta_t/V3; 
        M3(step+1) = M3(step) - JM2(step)*A23*delta_t/V3; 
         
        % output concentration/mass at the exit of the diffusion 
hole(s), J2 
        C_conduit = C2(step); 
        M_conduit = M2(step); 
        % output receiver chamber concentration in mg/ml 
        C_out_all(step) = C3(step); 
        M_out_all(step) = mass_reservoir - M1(step); 
        % cumulative concentration for flushed samples 
        C_cumulative(step) = C_out_all(step) + sum(C_out_collections); 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
         
         
     
    %%%%%%%%%code for nerve stump in-vivo model%%%%%%%%% 
    else 
%         syms conc1 conc2 conc3 
%         C2_eq(conc1,conc3) = solve(-D_coeff*(conc1-conc2)/L12*A12 == 
-D_coeff*(conc2-conc3)/L23*A23, conc2); 
%         C2(step) = C2_eq(C1(step),C3(step)); 
        %simplified C2 equation 
        C2(step) = (A12*L23*C1(step) + A23*L12*C3(step))/(A12*L23 + 
A23*L12); 
        M2(step) = (A12*L23*M1(step) + A23*L12*M3(step))/(A12*L23 + 
A23*L12); 
        J1(step) = -D_coeff*(C1(step)-C2(step))/L12; 
        JM1(step) = -D_coeff*(M1(step)-M2(step))/L12; 
        J2(step) = -D_coeff*(C2(step)-C3(step))/L23; 
        JM2(step) = -D_coeff*(M2(step)-M3(step))/L23; 
        C1(step+1) = C1(step) + J1(step)*A12*delta_t/V1; 
        M1(step+1) = M1(step) + JM1(step)*A12*delta_t/V1; 
         
        %Output conduit concentration at 'collection' times 
        for count = 1:size(collections,2) 
            if collections(count) == time(step) 
                %output receiver chamber concentration at collection 
times 
                C_out_collections(collection_count) = C2(step); 
                M_out_collections(collection_count) = M2(step); 
                t_collections(collection_count) = time(step); 
                collection_count = collection_count + 1; 
            end 
        end 
         
        % output internal steady-state concentration/mass at the exit 
of 
        % diffusion hole 
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        C_conduit(step) = C2(step); 
        M_conduit(step) = M2(step); 
        % output total drug diffused concentration in mg/ml; ignore 
first 
        % point 
        if step ~=1 
            C_out_all(step) = C_out_all(step-1) + C_conduit(step); 
            M_out_all(step) = mass_reservoir - M1(step); 
        end 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 




In vitro Release Parameters 
The following code is the script that takes input parameters for the nerve conduit, 





% Scott Ho 
% Created: 5/8/14 
%  
% Diffusion Modelling: Model used to determine proper hole sizes and 
% expected diffusion rate for receiver chamber 
% 
  
%% NGF/Dextran Parameters 
  




%%%%%%%%%% Input Parameters: NGF/Dextran + Rat Single 
Conduit %%%%%%%%%%%% 
conc_reservoir = 5;        %mg/ml 
%time of tests in days 
time_i = 0; 
time_f = 30; 
time_i_hr = time_i*24; 
time_f_hr = time_f*24; 
%number of iterations: over 200 iterations should be accurate to 
within .1% 
%cumulative diffusion; for under 1% collection error, use 400+ 
%iterations 
iterations = (time_f_hr-time_i_hr)*2;       
collections = [time_i 1 2 4 7 14 21 28 time_f];    %in days 
no_collect = 0; 





hole_diam = 130;        %um 
hole_count = 1; 
  
%Rat Single Conduit size 
%length of reservoir: dual conduit 
res_length = 7;         %mm 
% prompt1 = 'Length of Drug Reservoir (mm)?\n'; 
% res_length = input(prompt1); 
%reservoir outer diameter: determined by outer conduit ID 
res_OD = 3.0;           %mm 
length_IC = 13;         %mm 
receiver_volume = 3;    %ml 
%Stump not used in receiver chamber tests; make dummy variable 
stump_length = 0;       %mm 
%reservoir inner diameter: determined by inner conduit OD 
res_ID = 2.3;           %mm 
%reservoir volume 
reservoir_volume = res_length*pi*((res_OD/2)^2-(res_ID/2)^2);   %ul 
fprintf('Reservoir Volume: %.1f ul \n\n', reservoir_volume) 
reservoir_volume = reservoir_volume*.001;                       %ul to 
ml 
%conduit inner diameter: matches 14G needle OD 
conduit_ID = 2.01;      %mm 





%%%%%%%%%% Input Parameters: NGF/Dextran + Mouse Dual 
Conduit %%%%%%%%%%% 
% conc_reservoir = 25;        %mg/ml 
% %time of tests in days 
% time_i = 0; 
% time_f = 30; 
% time_i_hr = time_i*24; 
% time_f_hr = time_f*24; 
% %number of iterations: over 200 iterations should be accurate to 
within .1% 
% %cumulative diffusion 
% iterations = (time_f_hr-time_i_hr)*2; 
% collections = [time_i 1 2 4 7 14 21 28 time_f];      %in days 
% no_collect = 0; 
% D_coeff_ngf = 1.26e-6;      %cm^2/sec 
%  
% %hole parameters 
% hole_diam = 130;         %um 
% hole_count = 1; 
%  
% %Mouse Dual Conduit size 
% %length of reservoir: dual conduit 
% res_length = 2;         %mm 
% % prompt1 = 'Length of Drug Reservoir (mm)?\n'; 
% % res_length = input(prompt1); 
% %reservoir outer diameter: determined by outer conduit ID 
% res_OD = 2.01;          %mm 
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% length_IC = 13;         %mm 
% receiver_volume = 3;  %ml 
% %Stump not used in receiver chamber tests; make dummy variable 
% stump_length = 0;       %mm 
% %reservoir inner diameter: determined by inner conduit OD 
% res_ID = 1.25;          %mm 
% %reservoir volume 
% reservoir_volume = res_length*pi*((res_OD/2)^2-(res_ID/2)^2);   %ul 
% fprintf('Reservoir Volume: %.1f ul \n\n', reservoir_volume) 
% reservoir_volume = reservoir_volume*.001;                       %ul 
to ml 
% %conduit inner diameter: matches 19G needle OD 
% conduit_ID = 1.067;     %mm 





%%% Target Parameters %%% 
%target range for accurate Dextran reading: 1000-50000 ng/ml, most 
%accurate between 1000-12,500 ng/ml 
  
%target range for accurate NGF reading: .5-20 ng/ml, most 




%use receiver chamber model of Fick's Diffusion 
receiver_model = 0; 
[conc_Receiver_all, conc_Receiver_collections, conc_cumulative, 
collect_time] = Ficks_Diffusion(receiver_model,... 
    D_coeff_ngf, conc_reservoir, thickness_IC, length_IC, time_i_hr, 
time_f_hr, iterations, ... 
    collections, reservoir_volume, hole_diam, hole_count, conduit_ID, 
receiver_volume, stump_length); 
  
%convert NGF/Dextran concentrations to ng/ml from mg/ml 
conc_Receiver_all = conc_Receiver_all.*1e6; 
conc_Receiver_collections = conc_Receiver_collections.*1e6; 
conc_cumulative = conc_cumulative.*1e6; 
  
%array of time values used in model 
time = linspace(time_i_hr, time_f_hr, iterations); 
collect_time_hr = collect_time/60/60; 
time_day = time/24; 




main = plot(time_day, conc_Receiver_all, 'r-'); 
hold on 
plot(collect_time_day, conc_Receiver_collections, 'k*') 
cumulative = plot(time_day, conc_cumulative, 'b-'); 










%compute percent release 
reservoir_mass = reservoir_volume*conc_reservoir*1e6;           %ng 
receiver_mass = conc_Receiver_all.*receiver_volume;             %ng 
collection_mass = conc_Receiver_collections.*receiver_volume;   %ng 
cumulative_mass = conc_cumulative.*receiver_volume;             %ng 
  
data_percent = receiver_mass./reservoir_mass*100; 
collection_percent = collection_mass./reservoir_mass*100; 
cumulative_percent = cumulative_mass./reservoir_mass*100; 
  
%Percent release plots 
figure(2) 
main = plot(time_day, data_percent, 'r-'); 
hold on 
ylim([0 100]) 
plot(collect_time_day, collection_percent, 'k*') 
cumulative = plot(time_day, cumulative_percent, 'b-'); 
title('Diffusion Model Percent Release through Guidance Conduit', 
'fontweight', 'bold'); %, 'fontsize', 12) 
xlabel('Time [Days]') 
ylabel('Percent Release [%]') 




%Print collection concentrations 
collection_array = [collections; conc_Receiver_collections]; 
fprintf('Collections for %.fx-%.fum hole(s):\n(For NGF: must remain 
between 1000-65000 ng/ml for accurate readings):\r', hole_count, 
hole_diam) 
fprintf('Day %.f: %.1f ng/ml\r', collection_array); 
fprintf('\n') 
  
%%%%%%%%%%%%% Testing for varying iteration counts %%%%%%%%%%%%%%%%%% 
% iterations2 = 3; 
% [ngf_NoCollect_all2, ngf_Receiver_collections2, collect_time2] = 
Ficks_Diffusion(receiver_model,... 
%     D_coeff_ngf, conc_reservoir, thickness_IC, length_IC, time_i_hr, 
time_f_hr, iterations2, ... 
%     no_collect, reservoir_volume, hole_diam, hole_count, conduit_ID, 
receiver_volume, stump_length); 
% ngf_NoCollect_all2 = ngf_NoCollect_all2.*1e6; 
% time2 = linspace(time_i_hr, time_f_hr, iterations2); 
% time_day2 = time2/24; 
%  
% iterations3 = 10; 
% [ngf_NoCollect_all3] = Ficks_Diffusion(receiver_model,... 
%     D_coeff_ngf, conc_reservoir, thickness_IC, length_IC, time_i_hr, 
time_f_hr, iterations3, ... 
%     no_collect, reservoir_volume, hole_diam, hole_count, conduit_ID, 
receiver_volume, stump_length); 




% time3 = linspace(time_i_hr, time_f_hr, iterations3); 
% time_day3 = time3/24; 
%  
% iterations4 = 100; 
% [ngf_NoCollect_all4] = Ficks_Diffusion(receiver_model,... 
%     D_coeff_ngf, conc_reservoir, thickness_IC, length_IC, time_i_hr, 
time_f_hr, iterations4, ... 
%     no_collect, reservoir_volume, hole_diam, hole_count, conduit_ID, 
receiver_volume, stump_length); 
% ngf_NoCollect_all4 = ngf_NoCollect_all4.*1e6; 
% time4 = linspace(time_i_hr, time_f_hr, iterations4); 
% time_day4 = time4/24; 
%  
% figure(1) 
% hold on 
% data2 = plot(time_day2, ngf_NoCollect_all2, 'm-'); 
% data3 = plot(time_day3, ngf_NoCollect_all3, 'c-'); 
% data4 = plot(time_day4, ngf_NoCollect_all4, 'g-'); 
% legend([main noreset data2 data3 data4], 'Collections: 0, 1, 3, 7, 
14, 21, 28',... 
%     'Iterate every minute (43,000)', '3 iterations', '10 
iterations',... 
%     '100 iterations', 'Location', 'NorthWest') 
% hold off 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
In vivo Release Parameters 
The following code is the script that takes input parameters for the nerve conduit, 





% Scott Ho 
% Created: 5/8/14 
%  
% Diffusion Modelling: Model used to determine proper hole sizes and 
% expected diffusion rate for in-vivo diffusion. Plotted concentration 
is 
% the concentration exhibited at the exit of the diffusion hole. 
% 
  
%% NGF/Dextran Parameters 
  








conc_reservoir = .0001;        %mg/ml 
%time of tests in days 
time_i = 0; 
time_f = 30; 
time_i_hr = time_i*24; 
time_f_hr = time_f*24; 
%number of iterations: over 200 iterations should be accurate to 
within .1% 
%cumulative diffusion; for under 1% collection error, use 400+ 
%iterations 
iterations = (time_f_hr-time_i_hr)*2;       
collections = linspace(0,60,16);    %in days 
no_collect = 0; 
D_coeff_ngf = 1.26e-6;  %cm^2/sec 
  
%hole parameters 
hole_diam = 130;        %um 
hole_count = 1; 
  
%Rat Single Conduit size 
%length of reservoir: dual conduit 
res_length = 7;         %mm 
% prompt1 = 'Length of Drug Reservoir (mm)?\n'; 
% res_length = input(prompt1); 
%reservoir outer diameter: determined by outer conduit ID 
res_OD = 3.0;           %mm 
length_IC = 13/2;       %mm 
receiver_volume = 3;    %ml 
%Stump not used in receiver chamber tests; make dummy variable 
stump_length = 0;       %mm 
%reservoir inner diameter: determined by inner conduit OD 
res_ID = 2.3;           %mm 
%reservoir volume 
reservoir_volume = res_length*pi*((res_OD/2)^2-(res_ID/2)^2);   %ul 
fprintf('Reservoir Volume: %.1f ul \n\n', reservoir_volume) 
reservoir_volume = reservoir_volume/1000;   %ul to ml 
%conduit inner diameter: matches 14G needle OD 
conduit_ID = 2.01;                          %mm 
thickness_IC = (res_ID-conduit_ID)/2;       %mm 
  
%calculate diffusion resistances 
%R1 = hole resistance 
R1 = thickness_IC/(pi*(hole_diam/1000/2)^2*hole_count); 
%R2 = inner conduit length to end from diffusion hole(s) 
R2 = length_IC/(pi*(conduit_ID/2)^2); 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% 
     
  
%%%%%%%%%% Input Parameters: NGF/Dextran + Mouse Dual 
Conduit %%%%%%%%%%% 
% conc_reservoir = .0001;        %mg/ml 
% %time of tests in days 
% time_i = 0; 
% time_f = 30; 
% time_i_hr = time_i*24; 
% time_f_hr = time_f*24; 
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% %number of iterations: over 200 iterations should be accurate to 
within .1% 
% %cumulative diffusion 
% iterations = (time_f_hr-time_i_hr)*2; 
% collections = [time_i .0833 .2917 .75 2 4.9167 11.9167 20 27 
time_f];      %in days 
% no_collect = 0; 
% D_coeff_ngf = 1.26e-6;      %cm^2/sec 
%  
% %hole parameters 
% hole_diam = 32;         %um 
% hole_count = 1; 
%  
% %Mouse Dual Conduit size 
% %length of reservoir: dual conduit 
% res_length = 2;         %mm 
% % prompt1 = 'Length of Drug Reservoir (mm)?\n'; 
% % res_length = input(prompt1); 
% %reservoir outer diameter: determined by outer conduit ID 
% res_OD = 2.01;          %mm 
% length_IC = 13;         %mm 
% receiver_volume = 3;  %ml 
% %Stump not used in receiver chamber tests; make dummy variable 
% stump_length = 0;       %mm 
% %reservoir inner diameter: determined by inner conduit OD 
% res_ID = 1.25;          %mm 
% %reservoir volume 
% reservoir_volume = res_length*pi*((res_OD/2)^2-(res_ID/2)^2);   %ul 
% fprintf('Reservoir Volume: %.1f ul \n\n', reservoir_volume) 
% reservoir_volume = reservoir_volume*.001;                       %ul 
to ml 
% %conduit inner diameter: matches 19G needle OD 
% conduit_ID = 1.067;     %mm 
% thickness_IC = (res_ID-conduit_ID)/2;   %mm 
%  
% %calculate diffusion resistances 
% %R1 = hole resistance 
% R1 = thickness_IC/(pi*(hole_diam/1000/2)^2); 
% %R2 = inner conduit length to end from diffusion hole(s) 







%use receiver chamber model of Fick's Diffusion 
invivo_model = 1; 
[conc_out_all, conc_Receiver_collections, conc_cumulative, 
collect_time, conc_conduit,... 
    ngf_conduit, ngf_out_all] = Ficks_Diffusion(invivo_model, 
D_coeff_ngf,... 
    conc_reservoir, thickness_IC, length_IC, time_i_hr, time_f_hr, 
iterations,... 





%convert NGF/Dextran concentrations to ng/ml from mg/ml 
conc_out_all = conc_out_all.*1e6; 
conc_Receiver_collections = conc_Receiver_collections.*1e6; 
conc_conduit = conc_conduit*1e6; 
  
%array of time values used in model 
time = linspace(time_i_hr, time_f_hr, iterations); 
collect_time_hr = collect_time/60/60; 
time_day = time/24; 
collect_time_day = collect_time_hr/24; 
  
%Plot conduit concentration at the diffusion hole exit 
figure(1) 
main = plot(time_day, conc_conduit, 'r-'); 
hold on 








%compute percent release 
reservoir_mass = conc_reservoir*reservoir_volume*1e6;   %ng 
mass_out = 
ngf_out_all*1e6;                             %ng                                
%ng 
  
mass_percent = mass_out./reservoir_mass*100; 
  
%Cumulative Percent release plot 
figure(2) 
percent = plot(time_day, mass_percent, 'r-'); 
hold on 
ylim([0 100]) 
title('Drug Percent Release from Guidance Conduit', 'fontweight', 
'bold'); %, 'fontsize', 12) 
xlabel('Time [Days]') 
ylabel('Cumulative Release [%]') 
legend('Percent Release', 'Location', 'NorthWest'); 
hold off 
  
%Cumulative Mass release per day 
figure(3) 
mass_day = plot(time_day, mass_out./time_day, 'r-'); 
hold on 
set(gca, 'YTickLabel', num2str(get(gca, 'YTick')')) 
title('Drug Mass Release from Guidance Conduit', 'fontweight', 
'bold'); %, 'fontsize', 12) 
xlabel('Time [Days]') 
ylabel('Cumulative Release [ng/day]') 
legend('Mass Release per Day', 'Location', 'NorthEast'); 
hold off 
  




percent_day = plot(time_day, mass_percent./time_day, 'r-'); 
hold on 
title('Drug Percent Release from Guidance Conduit', 'fontweight', 
'bold'); %, 'fontsize', 12) 
xlabel('Time [Days]') 
ylabel('Cumulative Release [%/day]') 
legend('Percent Release per Day', 'Location', 'NorthEast'); 
hold off 
  
%Print collection concentrations 
collection_array = [collections; conc_Receiver_collections]; 
fprintf('Collections for %.fx-%.fum hole(s):\n(For NGF: must remain 
between 1000-65000 ng/ml for accurate readings):\r', hole_count, 
hole_diam) 
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